13 October 2017 - Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute for Health and Care Excellence ruled that the drug was not a cost-effective treatment for skin cancer.

Erivedge (vismodegib) was made available to patients with advanced basal cell carcinoma unable to receive surgery or radiotherapy via the old CDF in 2013.

Following a reappraisal, NICE’s committee has now concluded however that the clinical benefit of the drug was unclear.

Read Pharma Times article